60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Stock Short Interest Climbs 88.4%

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 255,088 shares, an increase of 88.4% from the October 15th total of 135,408 shares. Approximately 7.4% of the shares of the company are sold short. Based on an average trading volume of 1,664,816 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, 60 Degrees Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $13.85.

Get Our Latest Report on 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Price Performance

Shares of NASDAQ SXTP opened at $0.52 on Monday. The stock’s fifty day moving average price is $0.94 and its two-hundred day moving average price is $1.65. 60 Degrees Pharmaceuticals has a one year low of $0.48 and a one year high of $8.62. The firm has a market cap of $1.82 million, a price-to-earnings ratio of -0.11 and a beta of 2.47.

60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16). The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.20 million. On average, equities analysts anticipate that 60 Degrees Pharmaceuticals will post -3.31 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

(Get Free Report)

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent. Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.

See Also

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.